Cardiac surgery results in significant impairment of ␤-adrenergic receptor (␤AR) function and is a cause of depressed myocardial function after surgery. We previously demonstrated that acute administration of ␤AR blocker during cardiopulmonary bypass (CPB) in an animal model of coronary artery bypass grafting (CABG) surgery attenuates ␤AR desensitization, whereas chronic oral ␤-blockade therapy in patients undergoing CABG surgery does not prevent it. Therefore we hypothesized that acute administration of metoprolol during CABG surgery would prevent acute myocardial ␤AR desensitization. A placebo-controlled initial phase (n ϭ 72) was performed whereby patients were randomized to either metoprolol 10 mg or placebo immediately before CPB. Then a second dose-finding study was performed where patients received 20 mg (n ϭ 20) or 30 mg (n ϭ 20) of metoprolol. Hemodynamic monitoring, atrial membrane adenylyl cyclase activity, atrial ␤AR density, and postoperative outcomes were measured. All groups showed similar decreases in isoproterenol-stimulated adenylyl cyclase activity (13%-24%). Cardiac output remained similar in all 4 groups throughout the intraoperative and postoperative period. In addition, patients receiving metoprolol 20 or 30 mg had less supraventricular arrhythmias 24 h postoperatively compared with patients receiving metoprolol 10 mg or placebo. Therefore, unlike our previous animal model of CABG surgery, metoprolol did not attenuate myocardial ␤AR desensitization. (Anesth Analg 2004;98:1224 -31) D espite improvements in cardiac surgical and anesthesia techniques, myocardial dysfunction is still common after coronary artery bypass graft (CABG) surgery. Depressed myocardial function can result in difficulty in separation from CPB, the need for inotropic drugs, and increased morbidity and cost (1). Cardiac surgery requiring cardiopulmonary bypass (CPB) results in significant impairment of ␤-adrenergic receptor (␤AR) function and is one of the causes of depressed myocardial function after cardiac surgery (2). Possible mechanisms underlying impaired ␤AR function include myocardial ischemia-reperfusion injury (3-5), hibernating and stunned myocardium (6,7), and acute myocardial ␤AR desensitization (8 -10). Previous studies have indicated that a major mechanism behind acute ␤AR desensitization is the markedly increased catecholamine levels found during cardiac surgery (8, 11, 12) resulting in agonist-induced desensitization. We have previously demonstrated that acute administration of ␤AR blocker during CPB in an animal model of CABG surgery attenuates ␤AR desensitization (13), whereas chronic oral ␤-adrenergic blocker therapy in patients undergoing CABG surgery does not protect patients from acute ␤AR desensitization (8). We now propose to test whether acute IV administration of ␤AR blocker in humans during CABG surgery can reduce acute myocardial ␤AR desensitization. Our hypothesis is that IV metoprolol, administered immediately before CPB, results in the attenuation of acute myocardial ␤AR desensitization.
Cardiac surgery results in significant impairment of ␤-adrenergic receptor (␤AR) function and is a cause of depressed myocardial function after surgery. We previously demonstrated that acute administration of ␤AR blocker during cardiopulmonary bypass (CPB) in an animal model of coronary artery bypass grafting (CABG) surgery attenuates ␤AR desensitization, whereas chronic oral ␤-blockade therapy in patients undergoing CABG surgery does not prevent it. Therefore we hypothesized that acute administration of metoprolol during CABG surgery would prevent acute myocardial ␤AR desensitization. A placebo-controlled initial phase (n ϭ 72) was performed whereby patients were randomized to either metoprolol 10 mg or placebo immediately before CPB. Then a second dose-finding study was performed where patients received 20 mg (n ϭ 20) or 30 mg (n ϭ 20) of metoprolol. Hemodynamic monitoring, atrial membrane adenylyl cyclase activity, atrial ␤AR density, and postoperative outcomes were measured. All groups showed similar decreases in isoproterenol-stimulated adenylyl cyclase activity (13%-24%). Cardiac output remained similar in all 4 groups throughout the intraoperative and postoperative period. In addition, patients receiving metoprolol 20 or 30 mg had less supraventricular arrhythmias 24 h postoperatively compared with patients receiving metoprolol 10 mg or placebo. Therefore, unlike our previous animal model of CABG surgery, metoprolol did not attenuate myocardial ␤AR desensitization.
(Anesth Analg 2004;98:1224 -31) D espite improvements in cardiac surgical and anesthesia techniques, myocardial dysfunction is still common after coronary artery bypass graft (CABG) surgery. Depressed myocardial function can result in difficulty in separation from CPB, the need for inotropic drugs, and increased morbidity and cost (1) . Cardiac surgery requiring cardiopulmonary bypass (CPB) results in significant impairment of ␤-adrenergic receptor (␤AR) function and is one of the causes of depressed myocardial function after cardiac surgery (2) . Possible mechanisms underlying impaired ␤AR function include myocardial ischemia-reperfusion injury (3) (4) (5) , hibernating and stunned myocardium (6, 7) , and acute myocardial ␤AR desensitization (8 -10) . Previous studies have indicated that a major mechanism behind acute ␤AR desensitization is the markedly increased catecholamine levels found during cardiac surgery (8, 11, 12) resulting in agonist-induced desensitization. We have previously demonstrated that acute administration of ␤AR blocker during CPB in an animal model of CABG surgery attenuates ␤AR desensitization (13), whereas chronic oral ␤-adrenergic blocker therapy in patients undergoing CABG surgery does not protect patients from acute ␤AR desensitization (8) . We now propose to test whether acute IV administration of ␤AR blocker in humans during CABG surgery can reduce acute myocardial ␤AR desensitization. Our hypothesis is that IV metoprolol, administered immediately before CPB, results in the attenuation of acute myocardial ␤AR desensitization. In addition, we examined a number of secondary clinical end-points potentially affected by ␤AR antagonists, such as incidence of supraventricular arrhythmias (SVA) and postoperative inotropic drug use.
Methods
Patients were enrolled after IRB approval and informed consent from the patient population undergoing primary CABG surgery at Duke University Medical Center. Exclusion criteria included history of severe hepatic dysfunction (␤AR antagonists are metabolized predominately by the liver), history of bronchospasm requiring daily bronchodilator therapy, pregnancy, preoperative inotropic drug use, or offpump coronary surgery. Two separate and consecutive studies were performed. First, a randomized placebo-controlled trial (n ϭ 72 patients) was performed whereby patients were administered either IV metoprolol 10 mg or placebo given immediately before initiation of CPB. Myocardial atrial samples were obtained just before metoprolol or placebo administration and immediately before termination of CPB; myocardial samples were analyzed for evidence of ␤AR desensitization. This study had sufficient power to detect a 20% difference in ␤AR desensitization between groups. From this study it was clear that 10 mg metoprolol did not prevent acute myocardial ␤AR desensitization. Therefore, a second dose-finding study was conducted. We chose the dose-finding methodology as opposed to a randomized-controlled trial because the effective dose of metoprolol required to prevent desensitization was not known. In this study, 2 consecutive groups of patients (n ϭ 20 each) were given 20 mg or 30 mg of metoprolol. At 20 mg of metoprolol, adenylyl cyclase assays were performed to test whether acute ␤AR desensitization had been attenuated as evidenced by a decrease of cyclic adenosine monophosphate (cAMP) response of 10% or less. If this end-point was not achieved, the dose was increased to 30 mg. We did not feel comfortable using doses larger than 30 mg in the setting of CPB as the literature was devoid of safety data on larger doses and we had no clinical experience of using doses larger than 30 mg. In addition, if serious adverse events were reported to the principal investigator (Dr. Schwinn), the study would be suspended while the data would be reviewed. The study was performed on an intention-to-treat basis with identical primary and secondary outcomes.
IV, radial artery, and pulmonary artery (PA) occlusion catheters were placed in all patients. Induction and maintenance of anesthesia was accomplished with midazolam (2-5 mg), fentanyl (1000 -1500 g), pentothal (200 -400 mg), and isoflurane (0.5%-1.5%) followed by placement of a transesophageal echocardiography (TEE) probe. All patients underwent nonpulsatile CPB, cooling to 32°C-34°C before rewarming. Data collection occurred as follows (schematic in Fig. 1 Atrial biopsies were each immediately snap-frozen in liquid nitrogen and stored at Ϫ80°C until assayed. Atrial biopsies were collected rather than ventricular biopsies for ethical reasons. There are a many studies supporting a similar response to agonist in atrium and ventricle (14 -16) , as well as in circulating lymphocytes (12, 17) .
Before separation from CPB, patients were rewarmed to a nasopharyngeal temperature of at least 36°C and the heart rate was optimized with epicardial pacing as needed. Hematocrit was maintained Ն0. 25 . Preload and afterload were optimized by fluid administration and vasoactive drugs. Inotropic drugs were added if clinically indicated to maintain a cardiac index more than 2.0 L/min/m 2 . If inotrope use was deemed necessary by the attending anesthesiologist, dopamine was instituted at 5 g · kg Ϫ1 · min Ϫ1 as a first-line drug, followed if necessary by epinephrine as second-line treatment; milrinone or intraaortic balloon counterpulsation were classified as third-line interventions. Only dopamine doses larger than 2.5 g · kg Ϫ1 · min Ϫ1 were defined are inotropic (18, 19) . Hemodynamic data (heart rate, rhythm, mean arterial blood pressure [MAP] , PA diastolic pressure, cardiac output and index) were collected at the following intervals: before anesthetic induction (baseline), immediately before commencement of CPB, after separation from CPB, on arrival in the intensive care unit (ICU), and at 4 h, 8 h, 16 h, and 24 h after admission to the ICU. Patients receiving preoperative ␤-adrenergic blockers had their therapy reinstituted on the first day postoperatively as per standard Duke protocol for heart rate Ͼ60 bpm and MAP Ͼ70 mm Hg. Supraventricular tachycardia were documented by 12-lead ECG.
Atrial membrane adenylyl cyclase activity was assessed using the method of Salomon et al. (20) , as modified and described previously (2) . Briefly, 20 L atrial membranes were incubated in triplicate with either water (basal), 100 M isoproterenol (ISO-MAX), 500 M isoproterenol (ISO-EC 50 ), 100 M zinterol (a selective ␤ 2 AR agonist), 10 mM sodium fluoride (mixed in a glass tube), or 5 mM manganese for 15 min at 37°C in a 50-L reaction mixture. The reaction mixture contained the following final drug concentrations: 30 mM Tris, 5 mM MgCl 2 , 0.8 mM EDTA, 0.12 mM adenosine triphosphate, 0.06 mM guanosine triphosphate, 2.8 mM phosphoenol-pyruvate, 50 g/mL myokinase, 0.1 mM cAMP, 10 g/mL pyruvate kinase, and 1 Ci ␣[
32 P]adenosine triphosphate. The reaction was stopped with 1 mL stop buffer (360 m adenosine triphosphate, 285 M cAMP, and 25,000 cpm/mL [
H]-cAMP). [
32 P]cAMP was isolated by sequential chromatography over Dowex columns using 1 mL alumina, and individual column recovery was normalized based on the recovery of a known amount of [ The primary end-point of this study was determined prospectively to be ␤AR signaling (isoproterenolstimulated adenylyl cyclase activity), with major clinical end-points being inotropic support and SVA. Inotropic support was measured as cumulative dose sums, inotrope hours, and percentage of patients receiving inotropes. Other comparisons are considered descriptive, including hemodynamic variables and baseline preoperative characteristics.
Data were tested for normal distribution, then either Wilcoxon's two-sample rank sum test or Student's t-test was used to test differences between different metoprolol doses and placebo in continuous demographic data, ISO-stimulated cAMP production, serum creatinine levels, hours in ICU, ␤AR receptor expression, cardiac output at each time point, inotrope hours, length of hospital stay, and hours intubated. Fisher's exact test was used to study the unadjusted association between group and the binary variables, including percentage of patients on inotropes, SVAs, 5% reduction of ISO-stimulated adenylyl cyclase activity, 10% reduction of ISO-stimulated adenylyl cyclase activity, and gender. Logistic regression was used to model inotrope hours and SVAs at each time point separately as a function of group and other covariates that included gender, age, race, congestive heart failure (CHF), body surface area (BSA), EF, aortic cross-clamp time, CPB time, hypertension, and diabetes mellitus. Generalized estimating equations logistic regression was used to study the rhythm response at the different time points as a function of group and covariates mentioned above. SAS software 
Results
To determine whether groups were similar with regard to preoperative and intraoperative characteristics, general characteristics such as age, BSA, gender, perioperative EF, and creatinine were examined; all were similar between groups (Table 1 ). In addition, comorbities such as diabetes, congestive heart failure (CHF), and hypertension, as well as preoperative use of ␤AR antagonists and angiotensin converting enzyme (ACE) inhibitors, were similar. In terms of intraoperative characteristics, all groups showed similar CPB times, aortic cross-clamp times, and number of coronary artery distal grafts (Table 2) .
To confirm hemodynamic effects of acute administration of ␤-adrenergic blockers in this setting, relevant clinical outcomes such as cardiac output and inotrope use were measured. Cardiac output remained similar in each group throughout the intraoperative and postoperative period, demonstrating no detrimental effect of ␤-adrenergic blockers on this variable (Table 2 and 3 ). In addition, the percentage of patients in each group receiving inotropes was not statistically different between groups, although there was a tendency for more inotropic drug use in the metoprolol 20 and 30 mg groups (Table 2) .
To test the primary hypothesis of attenuated ␤AR desensitization, we tested whether maximal or submaximal ISO-stimulated adenylyl cyclase activity was altered between groups. When examined as a continuous variable, all groups showed similar percentage decreases in ISO-stimulated adenylyl cyclase activity, i.e., percentage desensitization (percentage change from baseline: placebo, Ϫ18% Ϯ 8%; metoprolol 10 mg, Ϫ24% Ϯ 8%; metoprolol 20 mg, Ϫ13% Ϯ 17%; metoprolol 30 mg, Ϫ21% Ϯ 9%; Table 2 ). Figure 2 plots the percent ␤AR desensitization between placebo and each metoprolol group. In addition, when ␤AR desensitization was examined as a dichotomous variable, all groups were similar with regard to percentage of patients with Ͼ10% ␤AR desensitization ( Table 2) . Mean myocardial ␤AR density was 51 Ϯ 19 fmol/mg protein and percent change in ␤AR density (Pre-CPB to End-CPB) was not significant in any group of patients (placebo, Ϫ9%; metoprolol 10 mg, Ϫ8%; metoprolol 20 mg, Ϫ6%; and metoprolol 30 mg, Ϫ8%).
The incidence of SVA was different among groups. Specifically, there was a dose-dependent effect in that those patients receiving metoprolol 20 or 30 mg had significantly less SVAs in the 24 h postsurgery than those receiving metoprolol 10 mg or placebo (placebo, 10%; metoprolol 10 mg, 15%; metoprolol 20 mg, 0%; metoprolol 30 mg, 5%; Table 3 ). The study was not specifically powered for this outcome. Other outcomes such as length of stay in the ICU, number of hours intubated, and length of hospitalization were also similar among groups (Table 3) .
Discussion
The results from this human study are surprising. We expected some degree of attenuation of myocardial ␤AR desensitization based on our previous animal work (13) . However, the main results from this study contrast with our previous dog study in that metoprolol does not appear to attenuate myocardial ␤AR desensitization in humans during CABG surgery.
Myocardial ␤AR desensitization (also called "dampened ␤AR signal transduction") can occur as a result of changes in the receptor, changes in proteins involved in the signal transduction pathway, or both. Three mechanisms are involved in ␤AR desensitization at the receptor level (21) : uncoupling (disruption of receptor/G protein complex) (22, 23) , sequestration (movement of receptor from the cell surface to intracellular compartments) (24, 25) , and down-regulation (complex interplay between depressed receptor synthesis and destruction of sequestered receptors) (24) . These processes are thought to result from receptor phosphorylation by various kinases (second messenger stimulated kinases, protein kinase A and protein kinase C) as well as G proteincoupled receptor kinases (22, 23) . Elegant work over the last two decades examining mechanisms underlying ␤AR desensitization suggests that sympathetic activation leads to increased transmyocardial concentrations of norepinephrine and dampened ␤AR signal transduction (21, 24) . Thus our hypothesis: prevention of sympathetic activation of myocardial ␤ARs using ␤AR antagonists would attenuate myocardial ␤AR desensitization.
Perioperative changes in ␤AR function could result form a number of etiologies including ischemia and desensitization. Several studies have examined mechanisms underlying the effect of isolated myocardial ischemia on ␤AR signal transduction. The capacity of ␤AR agonists to stimulate adenylyl cyclase activity is enhanced during the first 15 minutes of myocardial ischemia because of acutely increased cell surface ␤AR density (26, 27) . With sustained ischemia, however, ISO-stimulated adenylyl cyclase activity decreases to less than control values, although ␤AR density remains increased (28) . During CABG surgery, aortic cross-clamp placement induces a reversible functional impairment of ␤AR signaling in myocardium in vivo, and we have previously demonstrated acute reduction in left ventricular myocardial ␤AR responsiveness at CPB termination despite stable ␤AR density in both dogs and humans (2, 8, 9) . In these studies ISO (␤-receptor level), sodium fluoride (Gs level), and manganese (adenylyl cyclase level) stimulated adenylyl cyclase activity was dampened; therefore, impaired myocardial ␤AR responsiveness to agonists during CPB is attributable to heterologous desensitization because the dampening included impairment of nonreceptor components of the signal transduction cascade (29) .
A study by Ungerer et al. (30) provides a possible mechanism for ␤AR dysfunction in the setting of acute myocardial ischemia. This study, using isolated perfused rat hearts, demonstrates time-dependent (10 -15 minute) increased ␤ARK activation (␤ARK is a ␤AR specific kinase responsible for receptor phosphorylation and desensitization) corresponding to functional inactivation of the ␤AR system occurring within the 15th to 30th minute of isolated ischemia. In the same time frame, other serine/threonine kinases, such as protein kinase C, have been shown to be activated during myocardial ischemia (31). Ungerer et al. also found that norepinephrine, perfused through the heart, increases membrane ␤ARK activity during normoxia, implying that receptor activation itself triggers translocation of the enzyme. Furthermore, in perfusion of ischemic hearts treated with desipramine before ischemia (desipramine suppresses ischemic norepinephrine release by almost 75%) (32), ␤ARK activity was suppressed compared with ischemic untreated hearts. Thus agonist occupation of cardiac ␤ARs during ischemia leads to induction and intracellular translocation of ␤ARK to the cell membrane.
In adult humans, ␤AR dysfunction after cardiac surgery occurs in the clinical setting of significant acute myocardial ischemia resulting in increased (2-20 fold) catecholamine concentrations (2, 8, 9, 11, 33) . Recently, Lee et al. (34) demonstrated that a single dose of 37.5 mg intrathecal bupivacaine prevents acute myocardial ␤AR desensitization and is associated Values are mean Ϯ sd. BSA ϭ body surface area; Gender (%M) ϭ percentage of patients of male gender; EF ϭ ejection fraction; Creat ϭ day 1 postoperative serum creatinine level; ␤Blk ϭ percentage patients receiving preoperative ␤-adrenergic blockers; ACE ϭ percentage of patients receiving angiotensin converting enzyme inhibitor drugs; DM ϭ diabetes; CHF ϭ congestive heart failure; HTN ϭ hypertension; Met ϭ metroprolol. 
Values are mean Ϯ sd. # Grafts ϭ number of coronary grafts use (venous or arterial); CPB ϭ cardiopulmonary bypass time; XCLMP ϭ aortic cross-clamp time; CO#1,2,3 ϭ cardiac outputs at time points #1 immediately before CPB; #2 immediately after CPB; #3 before transferring patient from operating room to intensive care unit; INOTRPS ϭ percentage of patients receiving inotropic drugs; ISOMAX ϭ maximally isoproterenol-stimulated adenylyl cyclase activity; ISOEC50 ϭ submaximal isoproterenol-stimulated adenylyl cyclase activity; Met ϭ metroprolol. Values are mean Ϯ sd. CO ϭ cardiac output, ICU ϭ hours after arrival in intensive care unit; INOHRS ϭ number of hours requiring inotropic support; SVAs ϭ % of patients with supraventricular arrhythmias; ICU ϭ length of stay in intensive care unit; LOS ϭ length of stay in hospital; Met ϭ metroprolol.
* P Ͻ 0.05.
with reduced plasma catecholamine levels (45) . These data, together with the study of Ungerer et al. (30) , indicate that increased myocardial catecholamine concentrations may, at least in part, be the stimulus for myocardial hyporesponsiveness seen during cardiac surgery. In support of this, blockade of ␤ARs with small dose ␤AR antagonist therapy has been shown to improve myocardial function in CHF ( The primary hypothesis of this study was to investigate whether intraoperative metoprolol attenuates myocardial ␤AR desensitization. We demonstrated that ISO-stimulated adenylyl cyclase activity is reduced similarly post-CPB in all groups; thus, ␤AR desensitization was not attenuated by intraoperative administration of metoprolol. Our previous work demonstrated that chronic ␤AR antagonists did not prevent acute myocardial ␤AR desensitization (8) . An explanation for this finding might be that clinically effective doses of preoperative ␤AR antagonists may not be present in sufficient concentration during CPB to prevent binding of extremely large concentrations of myocardial catecholamines generated during aortic cross-clamp, especially as cold inactivates monoamine oxidase and catechol-O-methyltransferase (33, 39) , further increasing myocardial catecholamine levels. Therefore, all patients, regardless of administration of preoperative ␤AR antagonists, appear to be at risk for acute intraoperative myocardial ␤AR dysfunction.
These findings are in contrast to our previously published animal model (13) . A possible explanation of our findings is that we were unable to provide a sufficient concentration of ␤-adrenergic blocker to antagonize adrenergic receptors on the myocardium. We limited the maximum metoprolol dose to 30 mg because of our concern that larger doses might be associated with bradycardia and negative inotropic effects that would continue into the post-CPB period. We were cognizant of the potential dose-response aspect of metoprolol; thus we designed our study in a dosefinding method to demonstrate clinical effect, biological effect, and also to ensure the safe use of ␤-adrenergic blockers in the intraoperative period. In fact, an increased requirement for intraoperative epicardial pacing for slow ventricular rate was seen in patients receiving 30 mg of metoprolol, preventing us from escalating to a larger dose of ␤-adrenergic blocker. We chose metoprolol for this study because it is relatively ␤ 1 AR selective and high lipophilic, has a moderate duration of action, and is readily available. Both lipophilicity and selectivity of ␤AR blockers have been shown to confer survival benefit over nonselective and poorly lipid soluble drugs such as propranolol and atenolol in CAD patients (40) .
One possible explanation for the failure of metoprolol to attenuate ␤AR desensitization after CABG with CPB is that ␤AR stimulation by increased catecholamines may not be the only cause of impaired ␤AR signaling. Non-catecholamine mediators have been implicated in the etiology of impaired ␤AR signaling after cardiac surgery (41) , whereas others have shown that proinflammatory cytokines can induce acute ␤AR desensitization (42) . In addition, myocardial ischemia itself impairs adenylyl cyclase activity (27, 28, 31) . Although prevention of catecholamine activation by spinal anesthesia has been shown to prevent ␤AR desensitization after CABG surgery, the prevention of indirect pathway activation could be responsible for the attenuation of ␤AR desensitization in this setting (34) . Therefore, it is likely that multiple mechanisms are involved in acute heterologous myocardial ␤AR desensitization in humans after CABG.
It is interesting that in this present research, and in our previous human study describing the occurrence of acute myocardial ␤AR desensitization (13) , there seemed to be widespread variation in ␤AR response to CPB. That is, some patients had very little or no desensitization whereas the majority had significant desensitization. Indeed describing the population as a single entity may not adequately reflect ␤AR desensitization biology. Six functionally important single nucleotide polymorphisms (SNPs) have been identified in the human ␤ 1 AR (2 SNPs) and ␤ 2 AR (4 SNPs) genes. SNPs are base-pair changes that occur reasonably frequently (Ͼ1%) in the DNA sequence of an individual. Many SNPs have no functional consequence, although some can alter expression or function of a protein. ␤AR SNPs include changes that alter receptor down-regulation and desensitization in response to agonist stimulation; clinically, these ␤AR polymorphisms predispose patients to (or protect them from) hypertension, CHF, and asthma. It is therefore possible that specific ␤AR SNPs influence acute myocardial ␤AR desensitization pathways during cardiac surgery. In fact, it may be that ␤AR antagonist therapy is helpful in some patients with particular ␤AR SNPs and not in others of a different genotype. Such genetic issues may be a reason why ␤AR antagonists work to prevent ␤AR desensitization in dogs and not humans.
Our secondary outcomes included the effect of a single dose of metoprolol on postoperative SVAs. We demonstrate that a single intraoperative dose of metoprolol (20 mg or 30 mg) reduces the incidence of SVAs by 75% compared with placebo up to 24 hours postoperatively. This effect appears to be dose-dependent, in that 20 mg or 30 mg of metoprolol reduces the incidence of SVAs, but 10 mg of metoprolol does not reduce this morbidity. There are perhaps more questions raised by the finding than there are answers. We do note that our incidence of SVAs is relatively small in the control group (10%). This may be attributable to our measurement of SVAs ending 24 hours postoperatively. In addition, our study was inadequately powered to investigate the effect of ␤-adrenergic blockers on postoperative SVAs. Also, our institutional practice is to commence oral ␤-adrenergic blocker therapy on the first postoperative day, thus data beyond 24 hours would be difficult to interpret. The peak incidence of SVAs is around the third postoperative day; this may explain the relatively small incidence of SVAs reported in our study compared with other publications (43, 44) . Overall, it is difficult to clinically interpret the relevance of this finding. Previous studies have noted that ␤-adrenergic blockers may reduce intraoperative or postoperative arrhythmias; however, there has been concern that a ␤-adrenergic blocker-induced reduction in postoperative arrhythmias may also result in decreased cardiac output (45, 46) . In our present study we note that there was no decrease in cardiac output associated with the use of up to 30 mg of metoprolol pre-CPB.
In conclusion, in contrast to our previous animal model of CABG surgery, acute administration of intraoperative ␤-adrenergic blocker did not attenuate myocardial ␤AR desensitization. Further work is required to investigate the discrepancy between the animal model and humans undergoing CABG surgery.
